Potential applications of global protein expression analysis (proteomics) in morbid obesity and bariatric surgery

Obesity Surgery

Volumn 18, Issue 7, 2008, Pages 905-910

  Brandacher, Gerald ^a   Golderer, Georg ^a   Kienzl, Katrin ^a   Werner, Ernst R ^a   Margreiter, Raimund ^a   Weiss, Helmut G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bariatric surgery; Biomarkers; Metabolic regulation; Morbid obesity; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

BARIATRIC SURGERY; GEL ELECTROPHORESIS; HUMAN; MASS SPECTROMETRY; MEDICAL DECISION MAKING; METABOLIC REGULATION; MORBID OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; WEIGHT CONTROL;

BARIATRIC SURGERY; BIOLOGICAL MARKERS; HUMANS; OBESITY, MORBID; PROTEOMICS;

EID: 46949109695     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-007-9337-2     Document Type: Review

References (21)

1. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med 2006;12:75-80.
2. Kral JG, Naslund E. Surgical treatment of obesity. Nat Clin Pract Endocrinol Metab 2007;3:574-83.
3. von Eyben FE, Kroustrup JP, Larsen JF, et al. Comparison of gene expression in intra-abdominal and subcutaneous fat: a study of men with morbid obesity and nonobese men using microarray and proteomics. Ann N Y Acad Sci 2004;1030:508-36.
4. Trevino V, Falciani F, Barrera-Saldana HA. DNA microarrays: a powerful genomic tool for biomedical and clinical research. Mol Med 2007;13:527-41.
5. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000;405:837-46.
6. Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol Mol Biol Rev 2002;66:39-63.
7. Kavallaris M, Marshall GM. Proteomics and disease: opportunities and challenges. Med J Aust 2005;182:575-9.
8. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-21.
9. Alban A, David SO, Bjorkesten L, et al. A novel experimental design for comparative two-dimensional gel analysis: two- dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44.
10. Tanaka K. Proceedings of the 2nd Japan-China joint symposium on mass spectrometry. Osaka, Japan; 1987.
11. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
12. Anderson NL, Anderson NG. The human plasma proteome-history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
13. Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004;15:219-27.
14. Maurya P, Meleady P, Dowling P, et al. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 2007;27:1247-55.
15. Birner-Gruenberger R, Hermetter A. Activity-based proteomics of lipolytic enzymes. Curr Drug Discov Technol 2007;4:1-11.
16. Klimcakova E, Moro C, Mazzucotelli A, et al. Profiling of adipokines secreted from human subcutaneous adipose tissue in response to PPAR agonists. Biochem Biophys Res Commun 2007;358:897-902.
17. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665-74.
18. Pieper R, Su Q, Gatlin CL, et al. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003;3:422-32.
19. Tonge R, Shaw J, Middleton B, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001;1:377-96.
20. Duncan MW, Hunsucker SW. Proteomics as a tool for clinically relevant biomarker discovery and validation. Exp Biol Med 2005;230:808-17.
21. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework biomarkers definitions working group. Clin Pharmacol Ther 2001;69:89-95.